{"id":"W3149611511","doi":"10.1093/ecco-jcc/jjab058","title":"Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study","year":2021,"lang":"en","type":"article","venue":"Journal of Crohn s and Colitis","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":147,"is_retracted":false,"has_abstract":true,"ca_institutions":"Research Canada; Covenant Health; University of Toronto; Grey Nuns Community Hospital; Mount Sinai Hospital; St. Paul's Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Takeda Pharmaceutical Company","keywords":"Medicine; Vedolizumab; Inflammatory bowel disease; Ulcerative colitis; Crohn's disease; Tumor necrosis factor alpha; Inflammatory Bowel Diseases; Tumor necrosis factors; Infliximab; Internal medicine; Disease; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002201814,0.0002024515,0.0002832311,0.00005764087,0.0001194584,0.0001119549,0.0001701273,0.00007496718,0.00001685172],"category_scores_gemma":[0.0005036151,0.0001420074,0.0001215247,0.00006584091,0.0001159226,0.00002329225,0.0001911518,0.0001707928,0.000001124816],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000332017,"about_ca_system_score_gemma":0.0002364181,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001281681,"about_ca_topic_score_gemma":0.001061685,"domain_scores_codex":[0.9983601,0.0002749143,0.0006170938,0.0002980978,0.0002143653,0.0002354433],"domain_scores_gemma":[0.9987515,0.0000931804,0.0003434586,0.0002915272,0.000284363,0.0002359431],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003021952,0.0002934608,0.9938757,0.00001332473,0.0001168599,0.0009485102,0.0003513275,0.000007468663,0.0003052131,0.00001848483,0.0005018716,0.0005457859],"study_design_scores_gemma":[0.003387067,0.0001462013,0.9943727,0.00005267725,0.00006478038,0.000004462113,0.0006057062,0.000006329486,0.0002359881,0.0001401535,0.0008082857,0.000175635],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9980496,0.0005389868,0.000001555883,0.0002828806,0.0001901035,0.0002562775,0.0005906932,0.00000392009,0.00008596606],"genre_scores_gemma":[0.9986075,0.0007105198,0.0000284102,0.0002803413,0.0001710871,0.000009268446,0.00004615942,0.00001594645,0.0001308192],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0009440481,"threshold_uncertainty_score":0.5790892,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01066192318520401,"score_gpt":0.250891219267981,"score_spread":0.240229296082777,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}